Difference between revisions of "Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative"

From blackwiki
Jump to navigation Jump to search
(Coronary heart disease events: One line break ought to be enough with parenthesis around. Template:Dfn to assist screen readers.)
(Replace pseudo-footnote with ref-tag footnotes (MOS:NOTES))
Line 2: Line 2:
 
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
 
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
 
|-
 
|-
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}*) !! style="width: 75px;" data-sort-type="number" | Placebo<br />(n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}}<br />(n = 8506)
+
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo<br />(n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}}<br />(n = 8506)
 
|-
 
|-
 
! colspan="2" | Absolute Risk per 10,000 Women-Years
 
! colspan="2" | Absolute Risk per 10,000 Women-Years
Line 8: Line 8:
 
| [[Coronary heart disease]] events<br />({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63)<br />1.32 (1.02–1.72)<br />1.18 (0.70–1.97) || 30<br />23<br />6 || 37<br />30<br />7
 
| [[Coronary heart disease]] events<br />({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63)<br />1.32 (1.02–1.72)<br />1.18 (0.70–1.97) || 30<br />23<br />6 || 37<br />30<br />7
 
|-
 
|-
| [[Invasive breast cancer]]<sup>a</sup> || 1.26 (1.00–1.59) || 30 || 38
+
| [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
 
|-
 
|-
 
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
 
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
Line 22: Line 22:
 
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
 
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
 
|-
 
|-
| Global Index<sup>b</sup> || 1.15 (1.03–1.28) || 151 || 170
+
| Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
 
|-
 
|-
| [[Deep vein thrombosis]]<sup>c</sup> || 2.07 (1.49–2.87) || 13 || 26
+
| [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
 
|-
 
|-
| [[Vertebral fracture]]s<sup>c</sup> || 0.66 (0.44–0.98) || 15 || 9
+
| [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
 
|-
 
|-
| Other [[osteoporotic fracture]]s<sup>c</sup> || 0.77 (0.69–0.86) || 170 || 131
+
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
 
|- class="sortbottom"
 
|- class="sortbottom"
| colspan="10" style="width: 1px;" | '''Abbreviations:''' WHI = {{No selflink|Women's Health Initiative}}. CEEs = {{No selflink|Conjugated estrogens}}. MPA = {{No selflink|Medroxyprogesterone acetate}}. '''Notes:''' Dosages were 0.625&nbsp;mg/day CEEs and 2.5&nbsp;mg/day MPA. '''Footnotes:''' <sup>a</sup> = Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer. <sup>b</sup> = A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes. <sup>c</sup> = Not included in Global Index. * = Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
+
| colspan="10" style="width: 1px;" | '''Abbreviations:''' WHI = {{No selflink|Women's Health Initiative}}. CEEs = {{No selflink|Conjugated estrogens}}. MPA = {{No selflink|Medroxyprogesterone acetate}}. '''Notes:''' Dosages were 0.625&nbsp;mg/day CEEs and 2.5&nbsp;mg/day MPA. '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
 
|}<!--
 
|}<!--
  
 
--><noinclude>
 
--><noinclude>
==References==
+
==Notes and references==
 
{{Reflist}}
 
{{Reflist}}
 +
{{Notelist}}
 +
{{Notefoot}}
 
[[Category:Medication templates]]
 
[[Category:Medication templates]]
 
[[Category:Templates that generate named references]]
 
[[Category:Templates that generate named references]]
 
</noinclude>
 
</noinclude>

Revision as of 09:27, 27 March 2019

Health risks in the CEEs/MPA substudy of the Women's Health Initiative

Event Relative Risk CEEs/MPA vs. placebo at 5.2 years (95% CI[note 1]) Placebo
(n = 8102)
CEEs/MPA
(n = 8506)
Absolute Risk per 10,000 Women-Years
Coronary heart disease events
( non-fatal myocardial infarction, death)
1.29 (1.02–1.63)
1.32 (1.02–1.72)
1.18 (0.70–1.97)
30
23
6
37
30
7
Invasive breast cancer[lower-alpha 1] 1.26 (1.00–1.59) 30 38
Stroke 1.41 (1.07–1.85) 21 29
Pulmonary embolism 2.13 (1.39–3.25) 8 16
Colorectal cancer 0.63 (0.43–0.92) 16 10
Endometrial cancer 0.83 (0.47–1.47) 6 5
Hip fracture 0.66 (0.45–0.98) 15 10
Death due to causes other than above 0.92 (0.74–1.14) 40 37
Global Index[lower-alpha 2] 1.15 (1.03–1.28) 151 170
Deep vein thrombosis[lower-alpha 3] 2.07 (1.49–2.87) 13 26
Vertebral fractures[lower-alpha 3] 0.66 (0.44–0.98) 15 9
Other osteoporotic fractures[lower-alpha 3] 0.77 (0.69–0.86) 170 131
Abbreviations: WHI = Template:No selflink. CEEs = Template:No selflink. MPA = Template:No selflink. Notes: Dosages were 0.625 mg/day CEEs and 2.5 mg/day MPA. Sources: [1][2]

Notes and references

  1. Warner Chilcott (March 2005). "ESTRACE TABLETS, (estradiol tablets, USP)" (PDF). fda.gov. Retrieved 27 November 2016.
  2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (July 2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial". JAMA. 288 (3): 321–33. doi:10.1001/jama.288.3.321. PMID 12117397.
  1. Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.
  2. A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.
  3. 3.0 3.1 3.2 Not included in Global Index.

Template:Notefoot


Cite error: <ref> tags exist for a group named "note", but no corresponding <references group="note"/> tag was found, or a closing </ref> is missing